CJC-1295 Standard Titration Schedule: Doses, Timing, and Escalation

What Is the Standard CJC-1295 Titration Schedule?

CJC-1295 titration follows a step-up model beginning at 100 mcg per dose. Prescribers hold each dose level for a minimum of two weeks before considering an increase of 100 mcg. Most clinical protocols published or referenced in endocrinology literature cap the escalation at 1,000 mcg for the DAC form and 300 to 500 mcg for the no-DAC form.

Why a Low Start Matters

Growth hormone-releasing hormone (GHRH) analogues amplify pulsatile GH secretion through pituitary somatotroph receptors. Starting too high triggers water retention, paresthesias, and transient hypoglycemia before the body adapts. The Teichman et al. Dose-escalation trial (J Clin Endocrinol Metab 2006, N=65) tested single intravenous and subcutaneous doses of CJC-1295 ranging from 30 to 60 mcg/kg and documented that higher doses produced proportionally greater IGF-1 elevations but also more frequent injection-site reactions and flushing. [1] A slow start minimises those side effects while still allowing the prescriber to identify the lowest effective dose.

Starting Dose Protocol

The 100 mcg starting dose is used regardless of whether the patient receives the DAC or no-DAC form. Body weight adjustments are not routinely applied in published outpatient protocols, because CJC-1295 acts on pituitary receptors rather than distributing broadly into adipose tissue the way small-molecule drugs do. Prescribers at some centres do weight-adjust after the first four weeks if IGF-1 response is below the age-adjusted mid-normal range.

Injection timing matters. For the no-DAC form, bedtime administration aligns the synthetic pulse with the dominant nocturnal GH surge, a physiological window well-documented in pituitary physiology research. [2] The DAC form's approximate eight-day half-life means timing within the day is less critical, but a consistent day of the week simplifies adherence.

How to Titrate CJC-1295 Step by Step

Titration follows three sequential phases: induction, escalation, and maintenance. Each phase has a defined duration and a specific decision rule.

Phase 1: Induction (Weeks 1 to 4)

Administer 100 mcg per dose at the assigned frequency (daily for no-DAC, once weekly for DAC). No dose change occurs during this period. Draw a baseline serum IGF-1 and fasting glucose before the first injection.

After four weeks, repeat IGF-1. If the result remains below the lower quartile of the age- and sex-adjusted reference range, the prescriber may escalate to 200 mcg. If IGF-1 is already in the upper half of normal, hold at 100 mcg. This approach matches the response-guided dose adjustment used in recombinant human growth hormone (rhGH) prescribing guidelines published by the Endocrine Society, which emphasise titrating to a target IGF-1 range rather than to a fixed dose ceiling. [3]

Phase 2: Escalation (Weeks 4 to 16)

Each 100 mcg step requires a two-to-four week hold. The practical escalation ladder looks like this:

| Week | Dose (no-DAC, daily) | Dose (DAC, weekly) | |------|----------------------|--------------------| | 1 to 4 | 100 mcg | 100 mcg | | 5 to 8 | 200 mcg | 200 mcg | | 9 to 12 | 300 mcg | 300 mcg | | 13 to 16 | 400 mcg (if needed) | 400 mcg (if needed) | | 17+ | 500 mcg max (no-DAC) | up to 1,000 mcg |

Dose increases stop when IGF-1 reaches the upper third of the age-adjusted normal range, or when the patient experiences side effects that do not resolve within seven days. A fasting insulin-like growth factor binding protein-3 (IGFBP-3) measurement can supplement IGF-1 at the 12-week mark, since IGFBP-3 reflects integrated GH exposure over a longer window. [4]

Phase 3: Maintenance

Once the patient achieves a target IGF-1, the dose is held. Recheck IGF-1 every three months for the first year, then every six months thereafter. Seasonal variation in IGF-1 is real: a study of 1,022 healthy adults published in the European Journal of Endocrinology found IGF-1 values roughly 5 to 8% lower in winter months. [5] Account for that when interpreting maintenance labs.

CJC-1295 With DAC vs. No DAC: Titration Differences

The two formulations differ in half-life, frequency, and the practical meaning of each dose escalation step.

DAC Formulation Pharmacokinetics

The Drug Affinity Complex technology attaches CJC-1295 to albumin in the bloodstream via a maleimide-thiol bond, extending the half-life from roughly 30 minutes (for native GHRH 1-29) to approximately eight days. Teichman et al. Measured mean IGF-1 increases of 28 to 39% above baseline after single subcutaneous doses and showed elevations sustained for six to eight days post-injection. [1] That sustained profile means one weekly injection can maintain continuous GH axis stimulation.

Weekly dosing also means that a dose change only occurs once per week, which simplifies monitoring. Blood draws for IGF-1 should be timed consistently, ideally 48 to 72 hours after the weekly injection, to avoid measuring the peak IGF-1 spike that occurs in the first 24 hours.

No-DAC (Modified GRF 1-29) Pharmacokinetics

Modified GRF 1-29 (mod GRF 1-29) shares the same four amino-acid substitutions as CJC-1295 but lacks the DAC linker. Its half-life is approximately 30 minutes, producing a single sharp GH pulse rather than sustained elevation. [6] Daily bedtime injections recreate a pattern closer to endogenous pulsatile GHRH release, which the pituitary requires to avoid receptor downregulation.

Because each injection produces a distinct pulse, the no-DAC form may be preferable for patients concerned about continuous IGF-1 elevation or those combining CJC-1295 with a GHRP/ghrelin mimetic like ipamorelin, where pulse amplification is the therapeutic goal rather than tonic stimulation.

Combination Dosing With Ipamorelin

Many protocols pair modified GRF 1-29 with ipamorelin 100 to 200 mcg in a single subcutaneous injection. Ipamorelin is a selective growth hormone secretagogue receptor (GHSR) agonist with a clean side-effect profile, producing minimal cortisol or prolactin elevation at standard doses. [7] The two peptides act on different receptors but converge on somatotroph GH release, producing a synergistic pulse amplitude greater than either agent alone.

When combining, titrate each peptide independently. Start both at 100 mcg and escalate the ipamorelin dose on the same schedule as the CJC-1295 component, capping ipamorelin at 300 mcg per dose.

Monitoring During CJC-1295 Titration

Monitoring is not optional. IGF-1 elevation without clinical oversight carries real risks, including acromegalic changes, fluid retention, and carpal tunnel syndrome, all of which are dose-dependent and reversible if caught early.

Required Lab Panel

Before starting CJC-1295 and at each titration checkpoint, obtain:

• Serum IGF-1 (ng/mL, age- and sex-adjusted)
• Fasting glucose and HbA1c (CJC-1295 may reduce insulin sensitivity at higher doses)
• Fasting insulin
• IGFBP-3 at baseline and 12 weeks
• Complete metabolic panel

The Endocrine Society's 2011 clinical practice guideline on adult GH deficiency recommends targeting IGF-1 within the age-adjusted normal range and checking it every one to two months during dose adjustments. [3] That same interval applies to CJC-1295 titration.

Side Effects That Require Dose Reduction

Dose reduction by one step (100 mcg) is indicated if any of the following appear and persist beyond seven days:

• Peripheral edema (fluid accumulation in hands, feet, or face)
• Paresthesias or numbness in the hands consistent with carpal tunnel syndrome
• Fasting glucose above 100 mg/dL on two consecutive checks if previously normal
• IGF-1 above the upper limit of the age-adjusted normal range on repeat testing

The FDA's guidance on recombinant GH products provides the clearest published framework for managing GH-axis overstimulation, and those principles translate directly to CJC-1295 monitoring. [8]

How Often to Check IGF-1

During active titration: every four weeks. During stable maintenance: every three months for the first year, then every six months. Any dose change restarts the four-week monitoring interval.

How Quickly Can You Increase CJC-1295?

The minimum interval between dose increases is two weeks for the no-DAC form and four weeks for the DAC form. The longer hold for the DAC form reflects the eight-day half-life: it takes roughly four half-lives (32 days) to approach steady-state at any given dose, and increasing before steady-state is reached risks overshooting the IGF-1 target. [1]

Evidence for the Two-Week Minimum

The Teichman et al. Pharmacokinetic trial showed that IGF-1 returned to baseline within 28 days after a single injection of CJC-1295 with DAC. [1] Escalating before that window closes means the patient is receiving an effective cumulative dose higher than intended. Most telehealth and academic protocols therefore use four weeks as the standard hold for the DAC form.

For the no-DAC form, steady-state is reached within two to three days given the short half-life. Two weeks provides enough time to observe tolerability and collect a repeat IGF-1. Prescribers who see strong early IGF-1 response (greater than 35% above baseline within the first two weeks) should hold rather than escalate, regardless of the minimum interval.

Upper Limits on Escalation Speed

No peer-reviewed RCT has tested weekly dose escalation of CJC-1295. The principle of minimum effective dose, described in endocrinology practice guidelines for growth hormone therapy in adults, argues against rapid titration even when tolerance appears good. [3] The goal is the lowest dose that achieves a target IGF-1 in the mid-to-upper normal range, not the highest dose the patient tolerates.

Special Populations and Dose Adjustments

Older Adults (Age 60 and Above)

IGF-1 declines with age. A 65-year-old man may have a normal IGF-1 of 75 to 120 ng/mL, compared to 150 to 250 ng/mL in a 35-year-old. Because the baseline is lower and the pituitary somatotroph pool is smaller, older patients often respond to lower CJC-1295 doses and reach their target IGF-1 at 100 to 200 mcg without further escalation. A 2020 meta-analysis of growth hormone secretagogue trials in adults over 60 years found that GHRH analogues increased IGF-1 by 20 to 38% from baseline at doses equivalent to 1 to 2 mcg/kg/day. [9] Start at 100 mcg and escalate only if the four-week IGF-1 remains below the age-adjusted lower quartile.

Patients With Elevated Fasting Glucose or Prediabetes

GH increases hepatic glucose output and reduces peripheral insulin sensitivity. The American Diabetes Association's Standards of Care note that GH excess (as in acromegaly) is associated with impaired glucose tolerance in 20 to 56% of patients. [10] CJC-1295 produces more modest IGF-1 elevations than supraphysiological GH, but prescribers should obtain a baseline HbA1c and recheck fasting glucose monthly during titration in any patient with a starting fasting glucose above 95 mg/dL. Dose escalation beyond 300 mcg is not recommended in patients with confirmed prediabetes (fasting glucose 100 to 125 mg/dL or HbA1c 5.7 to 6.4%) without close glycaemic monitoring. [10]

Women and Hormonal Context

Women generally have higher baseline IGF-1 than men of the same age due to oestrogen's stimulatory effect on hepatic IGF-1 production. Oral oestrogen (as in combined oral contraceptives) reduces hepatic IGF-1 because portal-delivered oestrogen suppresses hepatic GH receptor expression. [11] Women on oral oestrogen may need slightly higher CJC-1295 doses to reach the same IGF-1 target as women using transdermal oestrogen or no oestrogen. Adjust the IGF-1 reference range interpretation accordingly and document oestrogen route when interpreting labs.

Injection Technique and Reconstitution

CJC-1295 arrives as a lyophilised powder. Standard reconstitution uses bacteriostatic water: add 2 mL of bacteriostatic water to a 5 mg vial to yield a 2,500 mcg/mL (2.5 mg/mL) solution. At that concentration, a 100 mcg dose equals 0.04 mL on a 0.5 mL insulin syringe.

Store the reconstituted vial at 2 to 8°C. Use within 28 days. Do not freeze the reconstituted solution. Inject subcutaneously into the periumbilical abdomen or outer thigh, rotating sites to reduce lipohypertrophy. A 29- or 31-gauge, 5/16-inch (8 mm) needle is appropriate for most patients.

Pinch the skin, insert the needle at a 45-degree angle, and inject slowly over three to five seconds. Do not aspirate before injection for subcutaneous routes per updated injection technique guidance from the diabetes care literature, which eliminated aspiration from standard subcutaneous injection protocols. [12]

What the Evidence Actually Shows

CJC-1295 is not FDA-approved for any indication. The clinical evidence base is limited to a small number of pharmacokinetic and pharmacodynamic trials. The most cited is Teichman et al. (2006), a phase I/II dose-escalation study in 65 healthy adults aged 21 to 61 years. That trial tested intravenous and subcutaneous single doses from 30 to 60 mcg/kg with DAC. Subcutaneous doses produced mean IGF-1 increases of 28 to 39% above baseline, with elevations sustained for 14 days at the highest doses. [1] The authors concluded: "CJC-1295 was well tolerated and produced sustained, dose-dependent increases in GH and IGF-1 levels." [1]

A second trial by Ionescu and Frohman (J Clin Endocrinol Metab 2006) evaluated modified GHRH analogues and confirmed that amino-acid substitutions at positions 2, 8, 15, and 27 extend half-life by preventing dipeptidyl peptidase IV (DPP-IV) cleavage. [6] That structural finding explains why both the DAC and no-DAC forms of CJC-1295 outlast native GHRH 1-44 in circulation.

No randomised controlled trial has evaluated multi-week titration schedules for CJC-1295 specifically. Published dosing ladders in use at academic and telehealth centres derive from the pharmacokinetic data in these trials combined with clinical experience from rhGH prescribing. The Endocrine Society's adult GH deficiency guideline remains the closest applicable evidence-based framework. [3]

The absence of an FDA label means prescribers carry the full responsibility for monitoring. Ordering IGF-1 at every titration step is not optional; it is the primary safety checkpoint.

Storage, Stability, and Practical Logistics

Lyophilised CJC-1295 powder is stable at room temperature for up to 24 months if kept away from light and moisture. After reconstitution, the 28-day refrigerated window is firm: bacterial contamination risk increases with preservative depletion in bacteriostatic water beyond that point. [13]

Patients travelling across time zones do not need to adjust the injection time for the DAC form given its eight-day half-life. For the no-DAC form, shift the injection time by no more than two hours per night when crossing multiple time zones, targeting the new local bedtime within three to four days of arrival.

Do not mix CJC-1295 with ipamorelin in the same syringe unless the compounding pharmacy has verified compatibility of the specific reconstituted concentrations. Some compounding pharmacies supply pre-mixed vials; verify the concentration on the label before calculating the volume per dose.